NOVO NORDISK B

Explore why Morgan Stanley’s downgrade sent Novo Nordisk’s shares to their lowest level since June, the patent cliff threat, and what investors should watch for next.

How Novo Nordisk’s quantum‑chip gamble and obesity‑drug push could reshape Denmark’s pharma future and investor outlook.

Discover how Novo Nordisk’s new leadership shake‑up, Wegovy pill rollout in Germany, and 2 mg Ozempic launch in Norway are reshaping the obesity drug market and driving investor upside.

Explore how Novo Nordisk’s looming patent cliffs, new weight‑loss and hair‑loss opportunities, and defensive market status shape its future strategy.

Explore how Novo Nordisk’s Wegovy surge, regulatory risks and rivals like Eli Lilly shape its future growth and market strategy.

European Commission approves Wegovy tablet; Novo Nordisk sees strong investor lift and positive long‑term data on hemophilia candidate Denecimig.

Explore how Novo Nordisk’s 19% share surge reflects Wegovy’s success and a bold shift toward diversified biopharma growth.

Explore how Novo Nordisk’s share‑repurchase, Wegovy’s pricing gap, and modest earnings outlook shape investor sentiment amid market volatility.

Wegovy HD’s FDA approval boosts Novo Nordisk’s obesity lineup, delivering up to 20.7 % weight loss and positioning it to rival Lilly’s Mounjaro in the U.S. market.

New Nordisk’s stock jumps 10 % as FDA approves Wegovy tablet, opening a new U.S. revenue stream and boosting investor optimism.